Negative serum pregnancy test within  days prior to commencement of dosing in premenopausal women; women of non-childbearing potential may be included without serum pregnancy test if they are either surgically sterile or have been postmenopausal for >=  year; women must use an effective method of contraception from  days prior to randomization, throughout the treatment period, and for at least  months after the last dose of study treatment as directed by their physician; effective methods of contraception are defined as those which result in a low failure rate (i.e., less than % per year) when used consistently and correctly (for example implants, injectables, or intra-uterine devices); at the discretion of the investigator, acceptable methods of contraception may include total abstinence in cases where the lifestyle of the patient ensures compliance; (periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception); hormonal-based methods (e.g., oral contraceptives) are NOT permitted as contraception
Men, even if surgically sterilized (i.e. status post-vasectomy), who are sexually active with WOCBP must agree to follow instructions for effective barrier contraception from the time of signing consent and until  months after last dose of protocol-indicated treatment; periodic abstinence (e.g. calendar, ovulation, symptothermal, postovulation methods for the female partner) and withdrawal are not acceptable methods of contraception
Female patients who:\r\n* Are postmenopausal for at least  year before the screening visit, OR\r\n* Are surgically sterile, OR\r\n* If they are of childbearing potential, agree to practice two effective methods of contraception, at the same time, from the time of signing the informed consent form through  days after the last dose of study drug, OR\r\n* Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
Female patients must meet one of the following criteria:\r\n* Postmenopausal for at least  year prior to registration \r\n* Surgically sterile\r\n* Of childbearing potential and agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent form through  days after the last dose of study drug\r\n* Of childbearing potential and agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject\r\nNOTE: periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
Non-pregnant; women of childbearing potential must have a negative pregnancy test (human chorionic gonadotropin [HCG] serum or urine) within  days prior to study registration and to be repeated if not done within  days of starting chemotherapy; female subjects participating in this study should avoid becoming pregnant, and male subjects should avoid impregnating a female partner; non-sterilized female subjects of reproductive age and male subjects should use effective methods of contraception through defined periods during and after study treatment as specified below\r\n* Female subjects must meet one of the following:\r\n** Natural postmenopausal before the screening visit defined as no menses at any time in the preceding  consecutive months, or\r\n** Prior bilateral oophorectomy or bilateral tubal ligation, or\r\n** If they are of childbearing potential, agree to practice two effective methods of contraception per discussion with the treating physicians from the time of signing of the informed consent form through three months after the last dose of study drug, or\r\n** Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g., calendar, ovulation, symptothermal, post ovulation methods] and withdrawal are not acceptable contraception methods)\r\n* Male subjects, even if surgically sterilized (i.e., status post vasectomy) must agree to one of the following:\r\n** Practice effective barrier contraception during the entire study treatment period and through  days after the last study drug dose, or\r\n** Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g., calendar, ovulation, symptothermal, post ovulation methods] and withdrawal are not acceptable methods of contraception)
Female patients who:\r\n* Are postmenopausal for at least  year before the screening visit, OR\r\n* Are surgically sterile, OR\r\n* If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent form through  days after the last dose of study drug, AND\r\n* Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR\r\n* Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
Female subjects (unless postmenopausal for at least  year before the screening visit, or surgically sterilized), agree to practice two () effective methods of contraception at the same time, or agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject (Periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception) through  days after the last dose of maintenance therapy (see Section .. for definition of postmenopausal).
Male subjects (even if surgically sterilized) must agree to one of the following: practice effective barrier contraception (see Section ... for list of barrier methods), or practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of from the time of signing the informed consent through  days after last dose of maintenance therapy.
Female patients who:\r\n* Are postmenopausal for at least  year before the screening visit, OR\r\n* Are surgically sterile, OR\r\n* If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent form through  days after the last dose of study drug, OR\r\n* Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
Female patients must meet one of the following:\r\n* Postmenopausal for at least  year before the screening visit, OR\r\n* Surgically sterile, OR\r\n* If they are of childbearing potential:\r\n** Agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent form through  days after the last dose of study drug, AND\r\n** Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR \r\n** Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
Fertile men and women must use an effective method of contraception during treatment and for at least  months after completion of treatment as directed by their physician. Effective methods of contraception are defined as those which result in a low failure rate (i.e., less than % per year) when used consistently and correctly (e.g., implants, injectables, combined oral contraception or intra-uterine devices). At the discretion of the Investigator, acceptable methods of contraception may include total abstinence in cases where the lifestyle of the patient ensures compliance. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
Women of childbearing potential (WOCBP) must agree to use an adequate method of contraception during the study and until  months after the last treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until  months after the last treatment. Adequate methods of contraception include: total abstinence when this is in line with the preferred and usual lifestyle of the subject; periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
Female patients who:\r\n* Are postmenopausal for at least  year before the screening visit, OR\r\n* Are surgically sterile, OR\r\n* If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent form through  days after the last dose of study drug, OR\r\n* Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
Persons of childbearing potential, agree to one of the following:\r\n* Practice  effective methods of contraception, at the same time, from the time of signing the informed consent form through  days after the last dose of study drug, AND must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR\r\n* Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
Fertile men and women must use an effective method of contraception during treatment and for at least  months after completion of treatment as directed by their physician. Effective methods of contraception are defined as those that result in a low failure rate (i.e., less than % per year) when used consistently and correctly (e.g., implants, injectables, combined oral contraception or intra-uterine devices). At the discretion of the Investigator, acceptable methods of contraception may include total abstinence in cases where the lifestyle of the patient ensures compliance. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post ovulation methods] and withdrawal are not acceptable methods of contraception)
Female patients who: are postmenopausal for at least  year before the screening visit, OR are surgically sterile, OR if they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent form through  days after the last dose of study drug, OR agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods]), and latex or non-latex condom with or without a spermicidal agent, diaphragm with spermicide; cervical cap with a spermicide; sponge with a spermicide
A woman of childbearing potential (WOCBP) is a sexually mature female who: ) has not undergone a hysterectomy or bilateral oophorectomy; or ) has not been naturally postmenopausal for at least  consecutive months (i.e., has had menses at any time in the preceding  consecutive months); female patients who are WOCBP must agree to practice:\r\n*  effective methods of contraception, at the same time, from the time of signing the informed consent form through  days after the last dose of study drug, OR\r\n* True abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)\r\n* A WOCBP must have a negative serum or urine pregnancy test with a sensitivity of at least  mIU/mL within - days prior to and again within  hours of starting therapy with Revlimid; females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Fertile men and women must use an effective method of contraception during treatment and for at least  months after completion of treatment as directed by their physician; effective methods of contraception are defined as those which result in a low failure rate (i.e., less than % per year) when used consistently and correctly (e.g., implants, injectables, combined oral contraception or intra-uterine devices); at the discretion of the investigator, acceptable methods of contraception may include total abstinence in cases where the lifestyle of the patient ensures compliance; (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
For women:\r\n* Postmenopausal for at least  year before the screening visit, OR\r\n* Surgically sterile, OR\r\n* If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent through  days after the last dose of study drug OR agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient (periodic abstinence [e.g, calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception)
Fertile men and women must use an effective method of contraception during treatment and for at least  months after completion of treatment as directed by their physician; effective methods of contraception are defined as those which result in a low failure rate (i.e., less than % per year) when used consistently and correctly (for example implants, injectables, combined oral contraception or intra-uterine devices); at the discretion of the investigator, acceptable methods of contraception may include total abstinence in cases where the lifestyle of the patient ensures compliance (periodic abstinence [e.g. calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
Female patients who:\r\n* Are postmenopausal for at least  year before the screening visit, OR\r\n* Are surgically sterile, OR\r\n* If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent form through  days after the last dose of study drug, OR\r\n* Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
Female patients who:\r\n* Are postmenopausal for at least  year before the screening visit, OR\r\n* Are surgically sterile, OR\r\n* If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent form through  days after the last dose of study drug, AND\r\n* Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR\r\n* Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
Female patients who:\r\n* Are postmenopausal for at least  year before the screening visit, OR\r\n* Are surgically sterile, OR\r\n* If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent form through  days after the last dose of study drug, OR\r\n* Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
Female patients who:\r\n* Are postmenopausal for at least  year before the screening visit, OR\r\n* Are surgically sterile, OR\r\n* If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent form through  days after the last dose of study drug, OR\r\n* Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
Female patients who:\r\n* Are postmenopausal for at least  year before the screening visit, OR\r\n* Are surgically sterile, OR\r\n* If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent form through  days after the last dose of study drug, AND\r\n* Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR \r\n* Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
Female patients have to fulfill one of the following: \r\n* Be postmenopausal for at least  year before the screening visit, OR\r\n* Be surgically sterile, OR \r\n* If of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent through  days after the last dose of study treatment\r\n* Patients who are using oral contraceptives as a method of contraception, and are sexually active, should use another effective contraceptive method, AND must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR \r\n* Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
Female patients who: \r\n* Are postmenopausal for at least  year before the screening visit, OR \r\n* Are surgically sterile, OR \r\n* If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent form through  days after the last dose of study drug, AND \r\n* Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR \r\n* Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
Female patients who: \r\n* Are postmenopausal for at least  months before the screening visit, OR\r\n* Are surgically sterile, OR \r\n* If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent form through  days after the last dose of study drug, OR \r\n* Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
Female patients who:\r\n* Are postmenopausal for at least  year before the screening visit, OR\r\n* Are surgically sterile, OR\r\n* If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent through  days after the last dose of study drug, or agree to completely abstain from heterosexual intercourse; periodic abstinence (calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception)
Female patients who:\r\n* Are postmenopausal for at least  year before the screening visit, OR\r\n* Are surgically sterile, OR\r\n* If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent form through  days after the last dose of study drug, OR\r\n* Agree to practice true abstinence or exclusively non-heterosexual activity when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
Female patients who:\r\n* Are postmenopausal for at least  year before the screening visit, OR\r\n* Are surgically sterile, OR\r\n* Are of childbearing potential, \r\n** Agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent form through  days after the last dose of study drug, OR\r\n** Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
Fertile men and women must use an effective method of contraception during treatment and for at least  months after completion of treatment as directed by their physician; effective methods of contraception are defined as those which result in a low failure rate (i.e., less than % per year) when used consistently and correctly (for example implants, injectables, combined oral contraception or intra-uterine devices); at the discretion of the investigator, acceptable methods of contraception may include total abstinence in cases where the lifestyle of the patient ensures compliance; (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
Negative serum pregnancy test within  days prior to commencement of dosing in premenopausal women; women of non-childbearing potential may be included without serum pregnancy test if they are either surgically sterile or have been postmenopausal for >=  year; fertile men and women must use an effective method of contraception during treatment and for at least  months after completion of treatment as directed by their physician; effective methods of contraception are defined as those which result in a low failure rate (i.e., less than % per year) when used consistently and correctly (for example implants, injectables, combined oral contraception or intra-uterine devices); at the discretion of the Investigator, acceptable methods of contraception may include total abstinence in cases where the lifestyle of the patient ensures compliance; (periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception)
Female patients who: are postmenopausal for at least  year before the screening visit, OR are surgically sterile, OR if they are childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent, during study treatment and for  days after the last dose of study treatment, AND \r\n* Must also adhere to guidelines of any treatment-specific pregnancy prevention program, if applicable, OR\r\n* Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g. calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
If they were of childbearing potential must have: had a negative pregnancy test with a sensitivity of at least  mIU/mL within  to  days and again within  hours prior to starting Cycle  of lenalidomide; either agreed to practice true abstinence, when this was in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal were not acceptable methods of contraception.) OR begun  reliable methods of birth control ( highly effective method and  additional effective method) at the same time, at least  days before starting study treatment through  days after the last dose of study treatment; and agreed to ongoing pregnancy testing AND must have also adhered to the guidelines of the RevAssist program (US participants), RevAid program (Canadian participants), iAccess program (Australian participants), RevMate program (Japanese participants) or The Lenalidomide Pregnancy Risk Minimisation Plan as outlined in the Study Manual (all other participants who were not using commercial supplies). Male patients, even if surgically sterilized (ie, status postvasectomy), who:
Female patients who:\r\n* Are postmenopausal for at least  year before the screening visit, OR\r\n* Are surgically sterile, OR \r\n* If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent form through  days after the last dose of study drug, OR \r\n* Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g., calendar ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception); if patient is female and of childbearing potential, she must have a negative serum beta human chorionic gonadotropin (-HCG) test within  days prior to registration and consent to ongoing pregnancy testing during the course of the study
Female patients must be:\r\n* Postmenopausal for at least  year before the screening visit, OR\r\n* Surgically sterile, OR\r\n* If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent form through  days after the last dose of study drug, OR\r\n* Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
Fertile men and women must use an effective method of contraception during treatment and for at least  months after completion of treatment as directed by their physician; effective methods of contraception are defined as those which result in a low failure rate (i.e., less than % per year) when used consistently and correctly (for example implants, injectables, combined oral contraception or intra-uterine devices); at the discretion of the investigator, acceptable methods of contraception may include total abstinence in cases where the lifestyle of the patient ensures compliance; (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
Female patients who:\r\n* Are postmenopausal for at least  year before the screening visit, OR\r\n* Are surgically sterile, OR\r\n* If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent form through  days after the last dose of study drug, AND\r\n* Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR\r\n* Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
Female patients who:\r\n* Are postmenopausal for at least  year before the screening visit, OR\r\n* Are surgically sterile, OR\r\n* If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent form through  days after the last dose of study drug, AND\r\n* Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR \r\n* Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent through  days after the last dose of study drug, or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant (periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception).
Female patients who:\r\n* Are postmenopausal for at least  year before the screening visit, OR\r\n* Are surgically sterile, OR\r\n* If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent form through  days after the last dose of study drug, OR\r\n* Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject (periodic abstinence and withdrawal are not acceptable methods of contraception)
Fertile men and women must use an effective method of contraception during treatment and for at least  months after completion of treatment as directed by their physician; effective methods of contraception are defined as those, which result in a low failure rate (i.e., less than % per year) when used consistently and correctly (for example implants, injectables, combined oral contraception or intra-uterine devices); at the discretion of the investigator, acceptable methods of contraception may include total abstinence in cases where the lifestyle of the patient ensures compliance; (periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception)
Female patients who:\r\n* Are postmenopausal for at least  year before the screening visit, OR\r\n* Are surgically sterile, OR\r\n* If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent form through  days after the last dose of study drug, OR\r\n* Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
